U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H35NOS
Molecular Weight 337.563
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULOCTIDIL

SMILES

CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1

InChI

InChIKey=BFCDFTHTSVTWOG-PXNSSMCTSA-N
InChI=1S/C20H35NOS/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3/h11-14,16-17,20-22H,5-10,15H2,1-4H3/t17-,20-/m0/s1

HIDE SMILES / InChI

Description

Suloctidil is considered to be calcium antagonist. In addition to its vascular antispasmodic activity, suloctidil affects blood platelets and enhances brain energy metabolism. Suloctidil was being evaluated in many clinical trials for use in dementia and thrombotic disorders. Suloctidil induces hepatotoxicity.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.45 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Curative
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
200 mg t.i.d.
Route of Administration: Oral
In Vitro Use Guide
Suloctidil (10 microM) stimulated the release of prostacyclin (PGI2) from the rabbit aorta, the dog vena cava and the dog portal vein, in vitro.